The aorta is the largest artery in the body, leading from the heart down to the abdomen. Atherosclerosis (a common condition where arteries become clogged with plaques, causing them to harden and narrow) weakens and thins the vessel walls and aneurysms can occur, which can rupture, causing massive internal bleeding and rapid death if left untreated. The standard treatment method for an Abdominal/Thoracic Aortic Aneurysm (AAA/TAA) repair is open surgery, however endovascular aneurysm repair (EVAR) procedures - minimally invasive methods where an endovascular stent graft is inserted via a catheter through a small incision in the groin - have become increasingly popular with benefits including reduced risks (especially for older/unfit patients), shorter hospital stays, quicker recovery, reduced complications and lower mortality rates. Whilst endovascular stent-graft placement has revolutionized the treatment of AAA/TAA, it is not without complications. The effective functioning of the stent-graft depends upon a very close fit between the stent and the vessel wall; however, patients with atherosclerosis are highly likely to have calcified plaque deposits and other vessel wall abnormalities which can compromise the effective fit of the inserted stent. ~40% of patients experience blood leakage (endoleaks) around the outside of the stent-graft, which can result in the aneurysm refilling and continuing to grow. Repair of Type I endoleaks (most critical) requires additional surgery and treatment which is expensive, increases complications, risks and mortality. Current approaches focus on the 'repair' of endoleaks once presented. There is a clear unmet need for a device that can actively 'prevent' the costly and life-threatening problem of endoleaks in endovascular stent-graft placement. Newtec Vascular Products has patented a novel vascular surgery device 'StentSeal', designed to **prevent** endoleaks through creating a perfect seal between the stent graft and the vessel wall, and improve outcomes in both AAA and TAA repair (with transferability to other vessels). Impacts include significant cost savings, improved patient outcomes, reduced complications/mortality and improved cost-effectiveness of EVAR. The focus of this project is to prove the feasibility of the approach through detailed market research and materials investigation, device design and concept development (progressing the concept to TRL3). Project outputs will inform next stages of R&D (prototyping, pre-clinical testing, first-in-man clinical trial), prior to commercialisation in the global Aortic Stent Graft market, estimated to reach $4.5billion by 2028\. The project will deliver significant export led growth for Newtec, a substantial ROI, increased employment and further opportunity for R&D investment.

"Clip devices are widely used in surgery where the occlusion/ligation of vessels is required. Mechanical ligation of the vessel using clip devices can offer major advantages including early ambulation and decreased hospital resource utilisation; however, they are also associated with incidences of bleeding through device failure and other more significant complications such as adhesion formation, erosion into surrounding structures and infection (minor complications in up to 7.2% of cases, major complications in up to 3%). Commonly used metal clips ('staples') have sharp, erosive ends and can cause tissue damage; their thin cross-sectional area promotes 'cheese-wiring' through vessels; the clips have no locking mechanism, are not secure and are easily dislodged. Current polymer-based clips have 'longitudinal' designs which still cause adhesion formation and problems with erosion into surrounding structures. Newtec Vascular Products seeks to advance their novel, patented, safe and secure vessel clip device 'VascuLok' suitable for use in surgery where vessel occlusion is required. VascuLok has a smooth 'rugby ball' profile shape with no 'edges', specifically designed to prevent adhesion formation/erosion in to nearby anatomical structures. VascuLok is manufactured from 'medical grade' polypropylene material (long history of safe use in man) which initiates an encapsulation response, further enhancing the locking mechanism by actively promoting the fibrous tissue capsule to form around the clip. The clip has a 'living' hinge, promoting a 'stand-off' from one clamp surface to another - giving an even clamp force over the entire clamp surface (provides security and prevents 'cheese-wiring' through clamped tissues), and a greater surface area for clamping. Its textured clamp surfaces allow better grip, and VascuLok clips are easy to remove if placed incorrectly. It causes no problems for subsequent MRI/CT scanning. This project will advance the technology from TRL5 to TRL7 through further development and prototype manufacturing, and demonstrate its clinical performance in a clinical study prior to regulatory certification and market launch initially into the vascular clip market from 2020\. Market need has been validated through extensive end-user consultation with Key Opinion Leading surgeons, and major interest shown. Strong transferability is envisaged in the cholecystectomy, male/female sterilisation markets and for neuro-surgery - targeted from 2022\. VascuLok will have a major impact =\> reducing serious complications during and after surgery, improving patient quality of life and reducing costs for the NHS. The project will deliver significant export led growth for Newtec, a substantial ROI, increased employment and further opportunity for R&D investment."

Cardiovascular diseases (CVD) account for ~31% of all global deaths. Atherosclerosis - hardening & narrowing of the arteries thus restricting blood supply to essential organs - is the dominant cause of CVD responsible for ~75% of all cardiovascular deaths. Surgeons perform complex bypass graft surgery using sections of a patient’s own healthy vessels or synthetic grafts to reconnect the blood supply when blood flow is restricted, however bypass graft failure rates are staggeringly high (~50%). The primary cause is Smooth Muscle Cell Neointimal Hyperplasia (SMCNIH), an overreaction of a natural healing process for the vessel wall in response to the trauma of surgery. The severe overgrowth of scar tissue causes the vessel lumen to narrow & constrain at the join thus restricting/blocking the blood flow - resulting in a high risk of clot formation. ~2M vascular grafts are implanted globally p.a. at >$8k/patient. Revision surgery after graft failure is expensive, carries further morbidity/mortality risk & causes severe distress to patients. Newtec recognises the major business opportunity that exists for a cost effective medical device that addresses this problem. The novel patented technology is a metal-free, drug-free device designed to support a vascular join & promote healthy healing following arterial or venous bypass surgery, promoting optimal healing of the joined vessels through its unique bilayered structure. PoC trials showed that the intimal hyperplasia (causing vessel lumen narrowing) reduced by a significant 30-50% - demonstrating the potential for routine use. This project will advance the tech to develop a validated ‘works-like’ ‘looks-like’ prototype to be used in a first in man trial prior to commercialisation. The device will be targeted towards the cardiovascular surgical device mkt (est. globally to reach ~$47.2bn by 2018) with initial applications in vascular grafts, peripheral grafts & subsequently coronary artery bypass grafts.

Cardiovascular diseases (CVD) account for ~31% of all global deaths. Atherosclerosis - hardening & narrowing of the arteries thus restricting blood supply to essential organs - is the dominant cause of CVD responsible for ~75% of all cardiovascular deaths. Surgeons perform complex bypass graft surgery using sections of a patient’s own healthy vessels or synthetic grafts to reconnect the blood supply when blood flow is restricted, however bypass graft failure rates are staggeringly high (~50%). The primary cause is Smooth Muscle Cell Neointimal Hyperplasia (SMCNIH), an overreaction of a natural healing process for the vessel wall in response to the trauma of surgery. The severe overgrowth of scar tissue causes the vessel lumen to narrow & constrain at the join thus restricting/blocking the blood flow - resulting in a high risk of clot formation. ~2M vascular grafts are implanted globally p.a. at >$8k/patient. Revision surgery after graft failure is expensive, carries further morbidity/mortality risk & causes severe distress to patients. Newtec recognises the major business opportunity that exists for a cost effective medical device that addresses this problem. The novel patented technology is a metal-free, drug-free device designed to support a vascular join & promote healthy healing following arterial or venous bypass surgery, promoting optimal healing of the joined vessels through its unique bilayered structure. PoC trials showed that the intimal hyperplasia (causing vessel lumen narrowing) reduced by a significant 30-50% - demonstrating the potential for routine use. This project will advance the tech to develop a validated ‘works-like’ ‘looks-like’ prototype to be used in a first in man trial prior to commercialisation. The device will be targeted towards the cardiovascular surgical device mkt (est. globally to reach ~$47.2bn by 2018) with initial applications in vascular grafts, peripheral grafts & subsequently coronary artery bypass grafts.

Cardiovascular diseases (CVD) account for ~31% of all global deaths. Atherosclerosis - hardening & narrowing of the arteries thus restricting blood supply to essential organs - is the dominant cause of CVD responsible for ~75% of all cardiovascular deaths. Surgeons perform complex bypass graft surgery using sections of a patient’s own healthy vessels or synthetic grafts to reconnect the blood supply when blood flow is restricted, however bypass graft failure rates are staggeringly high (~50%). The primary cause is Smooth Muscle Cell Neointimal Hyperplasia (SMCNIH), an overreaction of a natural healing process for the vessel wall in response to the trauma of surgery. The severe overgrowth of scar tissue causes the vessel lumen to narrow & constrain at the join thus restricting/blocking the blood flow - resulting in a high risk of clot formation. ~2M vascular grafts are implanted globally p.a. at >$8k/patient. Revision surgery after graft failure is expensive, carries further morbidity/mortality risk & causes severe distress to patients. Newtec recognises the major business opportunity that exists for a cost effective medical device that addresses this problem. The novel patented technology is a metal-free, drug-free device designed to support a vascular join & promote healthy healing following arterial or venous bypass surgery, promoting optimal healing of the joined vessels through its unique bilayered structure. PoC trials showed that the intimal hyperplasia (causing vessel lumen narrowing) reduced by a significant 30-50% - demonstrating the potential for routine use. This project will advance the tech to develop a validated ‘works-like’ ‘looks-like’ prototype to be used in a first in man trial prior to commercialisation. The device will be targeted towards the cardiovascular surgical device mkt (est. globally to reach ~$47.2bn by 2018) with initial applications in vascular grafts, peripheral grafts & subsequently coronary artery bypass grafts.

Cardiovascular diseases (CVD) account for ~31% of all global deaths. Atherosclerosis - hardening & narrowing of the arteries thus restricting blood supply to essential organs - is the dominant cause of CVD responsible for ~75% of all cardiovascular deaths. Surgeons perform complex bypass graft surgery using sections of a patient’s own healthy vessels or synthetic grafts to reconnect the blood supply when blood flow is restricted, however bypass graft failure rates are staggeringly high (~50%). The primary cause is Smooth Muscle Cell Neointimal Hyperplasia (SMCNIH), an overreaction of a natural healing process for the vessel wall in response to the trauma of surgery. The severe overgrowth of scar tissue causes the vessel lumen to narrow & constrain at the join thus restricting/blocking the blood flow - resulting in a high risk of clot formation. ~2M vascular grafts are implanted globally p.a. at >$8k/patient. Revision surgery after graft failure is expensive, carries further morbidity/mortality risk & causes severe distress to patients. Newtec recognises the major business opportunity that exists for a cost effective medical device that addresses this problem. The novel patented technology is a metal-free, drug-free device designed to support a vascular join & promote healthy healing following arterial or venous bypass surgery, promoting optimal healing of the joined vessels through its unique bilayered structure. PoC trials showed that the intimal hyperplasia (causing vessel lumen narrowing) reduced by a significant 30-50% - demonstrating the potential for routine use. This project will advance the tech to develop a validated ‘works-like’ ‘looks-like’ prototype to be used in a first in man trial prior to commercialisation. The device will be targeted towards the cardiovascular surgical device mkt (est. globally to reach ~$47.2bn by 2018) with initial applications in vascular grafts, peripheral grafts & subsequently coronary artery bypass grafts.

Cardiovascular diseases (CVD) account for ~31% of all global deaths. Atherosclerosis - hardening & narrowing of the arteries thus restricting blood supply to essential organs - is the dominant cause of CVD responsible for ~75% of all cardiovascular deaths. Surgeons perform complex bypass graft surgery using sections of a patient’s own healthy vessels or synthetic grafts to reconnect the blood supply when blood flow is restricted, however bypass graft failure rates are staggeringly high (~50%). The primary cause is Smooth Muscle Cell Neointimal Hyperplasia (SMCNIH), an overreaction of a natural healing process for the vessel wall in response to the trauma of surgery. The severe overgrowth of scar tissue causes the vessel lumen to narrow & constrain at the join thus restricting/blocking the blood flow - resulting in a high risk of clot formation. ~2M vascular grafts are implanted globally p.a. at >$8k/patient. Revision surgery after graft failure is expensive, carries further morbidity/mortality risk & causes severe distress to patients. Newtec recognises the major business opportunity that exists for a cost effective medical device that addresses this problem. The novel patented technology is a metal-free, drug-free device designed to support a vascular join & promote healthy healing following arterial or venous bypass surgery, promoting optimal healing of the joined vessels through its unique bilayered structure. PoC trials showed that the intimal hyperplasia (causing vessel lumen narrowing) reduced by a significant 30-50% - demonstrating the potential for routine use. This project will advance the tech to develop a validated ‘works-like’ ‘looks-like’ prototype to be used in a first in man trial prior to commercialisation. The device will be targeted towards the cardiovascular surgical device mkt (est. globally to reach ~$47.2bn by 2018) with initial applications in vascular grafts, peripheral grafts & subsequently coronary artery bypass grafts.

Cardiovascular diseases (CVD) account for ~31% of all global deaths. Atherosclerosis - hardening & narrowing of the arteries thus restricting blood supply to essential organs - is the dominant cause of CVD responsible for ~75% of all cardiovascular deaths. Surgeons perform complex bypass graft surgery using sections of a patient’s own healthy vessels or synthetic grafts to reconnect the blood supply when blood flow is restricted, however bypass graft failure rates are staggeringly high (~50%). The primary cause is Smooth Muscle Cell Neointimal Hyperplasia (SMCNIH), an overreaction of a natural healing process for the vessel wall in response to the trauma of surgery. The severe overgrowth of scar tissue causes the vessel lumen to narrow & constrain at the join thus restricting/blocking the blood flow - resulting in a high risk of clot formation. ~2M vascular grafts are implanted globally p.a. at >$8k/patient. Revision surgery after graft failure is expensive, carries further morbidity/mortality risk & causes severe distress to patients. Newtec recognises the major business opportunity that exists for a cost effective medical device that addresses this problem. The novel patented technology is a metal-free, drug-free device designed to support a vascular join & promote healthy healing following arterial or venous bypass surgery, promoting optimal healing of the joined vessels through its unique bilayered structure. PoC trials showed that the intimal hyperplasia (causing vessel lumen narrowing) reduced by a significant 30-50% - demonstrating the potential for routine use. This project will advance the tech to develop a validated ‘works-like’ ‘looks-like’ prototype to be used in a first in man trial prior to commercialisation. The device will be targeted towards the cardiovascular surgical device mkt (est. globally to reach ~$47.2bn by 2018) with initial applications in vascular grafts, peripheral grafts & subsequently coronary artery bypass grafts.

Cardiovascular diseases (CVD) account for ~31% of all global deaths. Atherosclerosis - hardening & narrowing of the arteries thus restricting blood supply to essential organs - is the dominant cause of CVD responsible for ~75% of all cardiovascular deaths. Surgeons perform complex bypass graft surgery using sections of a patient’s own healthy vessels or synthetic grafts to reconnect the blood supply when blood flow is restricted, however bypass graft failure rates are staggeringly high (~50%). The primary cause is Smooth Muscle Cell Neointimal Hyperplasia (SMCNIH), an overreaction of a natural healing process for the vessel wall in response to the trauma of surgery. The severe overgrowth of scar tissue causes the vessel lumen to narrow & constrain at the join thus restricting/blocking the blood flow - resulting in a high risk of clot formation. ~2M vascular grafts are implanted globally p.a. at >$8k/patient. Revision surgery after graft failure is expensive, carries further morbidity/mortality risk & causes severe distress to patients. Newtec recognises the major business opportunity that exists for a cost effective medical device that addresses this problem. The novel patented technology is a metal-free, drug-free device designed to support a vascular join & promote healthy healing following arterial or venous bypass surgery, promoting optimal healing of the joined vessels through its unique bilayered structure. PoC trials showed that the intimal hyperplasia (causing vessel lumen narrowing) reduced by a significant 30-50% - demonstrating the potential for routine use. This project will advance the tech to develop a validated ‘works-like’ ‘looks-like’ prototype to be used in a first in man trial prior to commercialisation. The device will be targeted towards the cardiovascular surgical device mkt (est. globally to reach ~$47.2bn by 2018) with initial applications in vascular grafts, peripheral grafts & subsequently coronary artery bypass grafts.

Cardiovascular diseases (CVD) account for ~31% of all global deaths. Atherosclerosis - hardening & narrowing of the arteries thus restricting blood supply to essential organs - is the dominant cause of CVD responsible for ~75% of all cardiovascular deaths. Surgeons perform complex bypass graft surgery using sections of a patient’s own healthy vessels or synthetic grafts to reconnect the blood supply when blood flow is restricted, however bypass graft failure rates are staggeringly high (~50%). The primary cause is Smooth Muscle Cell Neointimal Hyperplasia (SMCNIH), an overreaction of a natural healing process for the vessel wall in response to the trauma of surgery. The severe overgrowth of scar tissue causes the vessel lumen to narrow & constrain at the join thus restricting/blocking the blood flow - resulting in a high risk of clot formation. ~2M vascular grafts are implanted globally p.a. at >$8k/patient. Revision surgery after graft failure is expensive, carries further morbidity/mortality risk & causes severe distress to patients. Newtec recognises the major business opportunity that exists for a cost effective medical device that addresses this problem. The novel patented technology is a metal-free, drug-free device designed to support a vascular join & promote healthy healing following arterial or venous bypass surgery, promoting optimal healing of the joined vessels through its unique bilayered structure. PoC trials showed that the intimal hyperplasia (causing vessel lumen narrowing) reduced by a significant 30-50% - demonstrating the potential for routine use. This project will advance the tech to develop a validated ‘works-like’ ‘looks-like’ prototype to be used in a first in man trial prior to commercialisation. The device will be targeted towards the cardiovascular surgical device mkt (est. globally to reach ~$47.2bn by 2018) with initial applications in vascular grafts, peripheral grafts & subsequently coronary artery bypass grafts.

Cardiovascular diseases (CVD) account for ~31% of all global deaths. Atherosclerosis - hardening & narrowing of the arteries thus restricting blood supply to essential organs - is the dominant cause of CVD responsible for ~75% of all cardiovascular deaths. Surgeons perform complex bypass graft surgery using sections of a patient’s own healthy vessels or synthetic grafts to reconnect the blood supply when blood flow is restricted, however bypass graft failure rates are staggeringly high (~50%). The primary cause is Smooth Muscle Cell Neointimal Hyperplasia (SMCNIH), an overreaction of a natural healing process for the vessel wall in response to the trauma of surgery. The severe overgrowth of scar tissue causes the vessel lumen to narrow & constrain at the join thus restricting/blocking the blood flow - resulting in a high risk of clot formation. ~2M vascular grafts are implanted globally p.a. at >$8k/patient. Revision surgery after graft failure is expensive, carries further morbidity/mortality risk & causes severe distress to patients. Newtec recognises the major business opportunity that exists for a cost effective medical device that addresses this problem. The novel patented technology is a metal-free, drug-free device designed to support a vascular join & promote healthy healing following arterial or venous bypass surgery, promoting optimal healing of the joined vessels through its unique bilayered structure. PoC trials showed that the intimal hyperplasia (causing vessel lumen narrowing) reduced by a significant 30-50% - demonstrating the potential for routine use. This project will advance the tech to develop a validated ‘works-like’ ‘looks-like’ prototype to be used in a first in man trial prior to commercialisation. The device will be targeted towards the cardiovascular surgical device mkt (est. globally to reach ~$47.2bn by 2018) with initial applications in vascular grafts, peripheral grafts & subsequently coronary artery bypass grafts.

Cardiovascular diseases (CVD) account for ~31% of all global deaths. Atherosclerosis - hardening & narrowing of the arteries thus restricting blood supply to essential organs - is the dominant cause of CVD responsible for ~75% of all cardiovascular deaths. Surgeons perform complex bypass graft surgery using sections of a patient’s own healthy vessels or synthetic grafts to reconnect the blood supply when blood flow is restricted, however bypass graft failure rates are staggeringly high (~50%). The primary cause is Smooth Muscle Cell Neointimal Hyperplasia (SMCNIH), an overreaction of a natural healing process for the vessel wall in response to the trauma of surgery. The severe overgrowth of scar tissue causes the vessel lumen to narrow & constrain at the join thus restricting/blocking the blood flow - resulting in a high risk of clot formation. ~2M vascular grafts are implanted globally p.a. at >$8k/patient. Revision surgery after graft failure is expensive, carries further morbidity/mortality risk & causes severe distress to patients. Newtec recognises the major business opportunity that exists for a cost effective medical device that addresses this problem. The novel patented technology is a metal-free, drug-free device designed to support a vascular join & promote healthy healing following arterial or venous bypass surgery, promoting optimal healing of the joined vessels through its unique bilayered structure. PoC trials showed that the intimal hyperplasia (causing vessel lumen narrowing) reduced by a significant 30-50% - demonstrating the potential for routine use. This project will advance the tech to develop a validated ‘works-like’ ‘looks-like’ prototype to be used in a first in man trial prior to commercialisation. The device will be targeted towards the cardiovascular surgical device mkt (est. globally to reach ~$47.2bn by 2018) with initial applications in vascular grafts, peripheral grafts & subsequently coronary artery bypass grafts.

Cardiovascular diseases (CVD) account for ~31% of all global deaths. Atherosclerosis - hardening & narrowing of the arteries thus restricting blood supply to essential organs - is the dominant cause of CVD responsible for ~75% of all cardiovascular deaths. Surgeons perform complex bypass graft surgery using sections of a patient’s own healthy vessels or synthetic grafts to reconnect the blood supply when blood flow is restricted, however bypass graft failure rates are staggeringly high (~50%). The primary cause is Smooth Muscle Cell Neointimal Hyperplasia (SMCNIH), an overreaction of a natural healing process for the vessel wall in response to the trauma of surgery. The severe overgrowth of scar tissue causes the vessel lumen to narrow & constrain at the join thus restricting/blocking the blood flow - resulting in a high risk of clot formation. ~2M vascular grafts are implanted globally p.a. at >$8k/patient. Revision surgery after graft failure is expensive, carries further morbidity/mortality risk & causes severe distress to patients. Newtec recognises the major business opportunity that exists for a cost effective medical device that addresses this problem. The novel patented technology is a metal-free, drug-free device designed to support a vascular join & promote healthy healing following arterial or venous bypass surgery, promoting optimal healing of the joined vessels through its unique bilayered structure. PoC trials showed that the intimal hyperplasia (causing vessel lumen narrowing) reduced by a significant 30-50% - demonstrating the potential for routine use. This project will advance the tech to develop a validated ‘works-like’ ‘looks-like’ prototype to be used in a first in man trial prior to commercialisation. The device will be targeted towards the cardiovascular surgical device mkt (est. globally to reach ~$47.2bn by 2018) with initial applications in vascular grafts, peripheral grafts & subsequently coronary artery bypass grafts.

Cardiovascular diseases (CVD) account for ~31% of all global deaths. Atherosclerosis - hardening & narrowing of the arteries thus restricting blood supply to essential organs - is the dominant cause of CVD responsible for ~75% of all cardiovascular deaths. Surgeons perform complex bypass graft surgery using sections of a patient’s own healthy vessels or synthetic grafts to reconnect the blood supply when blood flow is restricted, however bypass graft failure rates are staggeringly high (~50%). The primary cause is Smooth Muscle Cell Neointimal Hyperplasia (SMCNIH), an overreaction of a natural healing process for the vessel wall in response to the trauma of surgery. The severe overgrowth of scar tissue causes the vessel lumen to narrow & constrain at the join thus restricting/blocking the blood flow - resulting in a high risk of clot formation. ~2M vascular grafts are implanted globally p.a. at >$8k/patient. Revision surgery after graft failure is expensive, carries further morbidity/mortality risk & causes severe distress to patients. Newtec recognises the major business opportunity that exists for a cost effective medical device that addresses this problem. The novel patented technology is a metal-free, drug-free device designed to support a vascular join & promote healthy healing following arterial or venous bypass surgery, promoting optimal healing of the joined vessels through its unique bilayered structure. PoC trials showed that the intimal hyperplasia (causing vessel lumen narrowing) reduced by a significant 30-50% - demonstrating the potential for routine use. This project will advance the tech to develop a validated ‘works-like’ ‘looks-like’ prototype to be used in a first in man trial prior to commercialisation. The device will be targeted towards the cardiovascular surgical device mkt (est. globally to reach ~$47.2bn by 2018) with initial applications in vascular grafts, peripheral grafts & subsequently coronary artery bypass grafts.

Cardiovascular diseases (CVD) account for ~31% of all global deaths. Atherosclerosis - hardening & narrowing of the arteries thus restricting blood supply to essential organs - is the dominant cause of CVD responsible for ~75% of all cardiovascular deaths. Surgeons perform complex bypass graft surgery using sections of a patient’s own healthy vessels or synthetic grafts to reconnect the blood supply when blood flow is restricted, however bypass graft failure rates are staggeringly high (~50%). The primary cause is Smooth Muscle Cell Neointimal Hyperplasia (SMCNIH), an overreaction of a natural healing process for the vessel wall in response to the trauma of surgery. The severe overgrowth of scar tissue causes the vessel lumen to narrow & constrain at the join thus restricting/blocking the blood flow - resulting in a high risk of clot formation. ~2M vascular grafts are implanted globally p.a. at >$8k/patient. Revision surgery after graft failure is expensive, carries further morbidity/mortality risk & causes severe distress to patients. Newtec recognises the major business opportunity that exists for a cost effective medical device that addresses this problem. The novel patented technology is a metal-free, drug-free device designed to support a vascular join & promote healthy healing following arterial or venous bypass surgery, promoting optimal healing of the joined vessels through its unique bilayered structure. PoC trials showed that the intimal hyperplasia (causing vessel lumen narrowing) reduced by a significant 30-50% - demonstrating the potential for routine use. This project will advance the tech to develop a validated ‘works-like’ ‘looks-like’ prototype to be used in a first in man trial prior to commercialisation. The device will be targeted towards the cardiovascular surgical device mkt (est. globally to reach ~$47.2bn by 2018) with initial applications in vascular grafts, peripheral grafts & subsequently coronary artery bypass grafts.

Cardiovascular diseases (CVD) account for ~31% of all global deaths. Atherosclerosis - hardening & narrowing of the arteries thus restricting blood supply to essential organs - is the dominant cause of CVD responsible for ~75% of all cardiovascular deaths. Surgeons perform complex bypass graft surgery using sections of a patient’s own healthy vessels or synthetic grafts to reconnect the blood supply when blood flow is restricted, however bypass graft failure rates are staggeringly high (~50%). The primary cause is Smooth Muscle Cell Neointimal Hyperplasia (SMCNIH), an overreaction of a natural healing process for the vessel wall in response to the trauma of surgery. The severe overgrowth of scar tissue causes the vessel lumen to narrow & constrain at the join thus restricting/blocking the blood flow - resulting in a high risk of clot formation. ~2M vascular grafts are implanted globally p.a. at >$8k/patient. Revision surgery after graft failure is expensive, carries further morbidity/mortality risk & causes severe distress to patients. Newtec recognises the major business opportunity that exists for a cost effective medical device that addresses this problem. The novel patented technology is a metal-free, drug-free device designed to support a vascular join & promote healthy healing following arterial or venous bypass surgery, promoting optimal healing of the joined vessels through its unique bilayered structure. PoC trials showed that the intimal hyperplasia (causing vessel lumen narrowing) reduced by a significant 30-50% - demonstrating the potential for routine use. This project will advance the tech to develop a validated ‘works-like’ ‘looks-like’ prototype to be used in a first in man trial prior to commercialisation. The device will be targeted towards the cardiovascular surgical device mkt (est. globally to reach ~$47.2bn by 2018) with initial applications in vascular grafts, peripheral grafts & subsequently coronary artery bypass grafts.

Cardiovascular diseases (CVD) account for ~31% of all global deaths. Atherosclerosis - hardening & narrowing of the arteries thus restricting blood supply to essential organs - is the dominant cause of CVD responsible for ~75% of all cardiovascular deaths. Surgeons perform complex bypass graft surgery using sections of a patient’s own healthy vessels or synthetic grafts to reconnect the blood supply when blood flow is restricted, however bypass graft failure rates are staggeringly high (~50%). The primary cause is Smooth Muscle Cell Neointimal Hyperplasia (SMCNIH), an overreaction of a natural healing process for the vessel wall in response to the trauma of surgery. The severe overgrowth of scar tissue causes the vessel lumen to narrow & constrain at the join thus restricting/blocking the blood flow - resulting in a high risk of clot formation. ~2M vascular grafts are implanted globally p.a. at >$8k/patient. Revision surgery after graft failure is expensive, carries further morbidity/mortality risk & causes severe distress to patients. Newtec recognises the major business opportunity that exists for a cost effective medical device that addresses this problem. The novel patented technology is a metal-free, drug-free device designed to support a vascular join & promote healthy healing following arterial or venous bypass surgery, promoting optimal healing of the joined vessels through its unique bilayered structure. PoC trials showed that the intimal hyperplasia (causing vessel lumen narrowing) reduced by a significant 30-50% - demonstrating the potential for routine use. This project will advance the tech to develop a validated ‘works-like’ ‘looks-like’ prototype to be used in a first in man trial prior to commercialisation. The device will be targeted towards the cardiovascular surgical device mkt (est. globally to reach ~$47.2bn by 2018) with initial applications in vascular grafts, peripheral grafts & subsequently coronary artery bypass grafts.

Cardiovascular diseases (CVD) account for ~31% of all global deaths. Atherosclerosis - hardening & narrowing of the arteries thus restricting blood supply to essential organs - is the dominant cause of CVD responsible for ~75% of all cardiovascular deaths. Surgeons perform complex bypass graft surgery using sections of a patient’s own healthy vessels or synthetic grafts to reconnect the blood supply when blood flow is restricted, however bypass graft failure rates are staggeringly high (~50%). The primary cause is Smooth Muscle Cell Neointimal Hyperplasia (SMCNIH), an overreaction of a natural healing process for the vessel wall in response to the trauma of surgery. The severe overgrowth of scar tissue causes the vessel lumen to narrow & constrain at the join thus restricting/blocking the blood flow - resulting in a high risk of clot formation. ~2M vascular grafts are implanted globally p.a. at >$8k/patient. Revision surgery after graft failure is expensive, carries further morbidity/mortality risk & causes severe distress to patients. Newtec recognises the major business opportunity that exists for a cost effective medical device that addresses this problem. The novel patented technology is a metal-free, drug-free device designed to support a vascular join & promote healthy healing following arterial or venous bypass surgery, promoting optimal healing of the joined vessels through its unique bilayered structure. PoC trials showed that the intimal hyperplasia (causing vessel lumen narrowing) reduced by a significant 30-50% - demonstrating the potential for routine use. This project will advance the tech to develop a validated ‘works-like’ ‘looks-like’ prototype to be used in a first in man trial prior to commercialisation. The device will be targeted towards the cardiovascular surgical device mkt (est. globally to reach ~$47.2bn by 2018) with initial applications in vascular grafts, peripheral grafts & subsequently coronary artery bypass grafts.

Cardiovascular diseases (CVD) account for ~31% of all global deaths. Atherosclerosis - hardening & narrowing of the arteries thus restricting blood supply to essential organs - is the dominant cause of CVD responsible for ~75% of all cardiovascular deaths. Surgeons perform complex bypass graft surgery using sections of a patient’s own healthy vessels or synthetic grafts to reconnect the blood supply when blood flow is restricted, however bypass graft failure rates are staggeringly high (~50%). The primary cause is Smooth Muscle Cell Neointimal Hyperplasia (SMCNIH), an overreaction of a natural healing process for the vessel wall in response to the trauma of surgery. The severe overgrowth of scar tissue causes the vessel lumen to narrow & constrain at the join thus restricting/blocking the blood flow - resulting in a high risk of clot formation. ~2M vascular grafts are implanted globally p.a. at >$8k/patient. Revision surgery after graft failure is expensive, carries further morbidity/mortality risk & causes severe distress to patients. Newtec recognises the major business opportunity that exists for a cost effective medical device that addresses this problem. The novel patented technology is a metal-free, drug-free device designed to support a vascular join & promote healthy healing following arterial or venous bypass surgery, promoting optimal healing of the joined vessels through its unique bilayered structure. PoC trials showed that the intimal hyperplasia (causing vessel lumen narrowing) reduced by a significant 30-50% - demonstrating the potential for routine use. This project will advance the tech to develop a validated ‘works-like’ ‘looks-like’ prototype to be used in a first in man trial prior to commercialisation. The device will be targeted towards the cardiovascular surgical device mkt (est. globally to reach ~$47.2bn by 2018) with initial applications in vascular grafts, peripheral grafts & subsequently coronary artery bypass grafts.

Cardiovascular diseases (CVD) account for ~31% of all global deaths. Atherosclerosis - hardening & narrowing of the arteries thus restricting blood supply to essential organs - is the dominant cause of CVD responsible for ~75% of all cardiovascular deaths. Surgeons perform complex bypass graft surgery using sections of a patient’s own healthy vessels or synthetic grafts to reconnect the blood supply when blood flow is restricted, however bypass graft failure rates are staggeringly high (~50%). The primary cause is Smooth Muscle Cell Neointimal Hyperplasia (SMCNIH), an overreaction of a natural healing process for the vessel wall in response to the trauma of surgery. The severe overgrowth of scar tissue causes the vessel lumen to narrow & constrain at the join thus restricting/blocking the blood flow - resulting in a high risk of clot formation. ~2M vascular grafts are implanted globally p.a. at >$8k/patient. Revision surgery after graft failure is expensive, carries further morbidity/mortality risk & causes severe distress to patients. Newtec recognises the major business opportunity that exists for a cost effective medical device that addresses this problem. The novel patented technology is a metal-free, drug-free device designed to support a vascular join & promote healthy healing following arterial or venous bypass surgery, promoting optimal healing of the joined vessels through its unique bilayered structure. PoC trials showed that the intimal hyperplasia (causing vessel lumen narrowing) reduced by a significant 30-50% - demonstrating the potential for routine use. This project will advance the tech to develop a validated ‘works-like’ ‘looks-like’ prototype to be used in a first in man trial prior to commercialisation. The device will be targeted towards the cardiovascular surgical device mkt (est. globally to reach ~$47.2bn by 2018) with initial applications in vascular grafts, peripheral grafts & subsequently coronary artery bypass grafts.